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Conclusions: In this unscreened European population of men 
with low risk prostate cancer, outcomes were better in the 
under the age of 60 cohort. Younger age should not be 
considered a contraindication for brachytherapy as opposed 
to surgery  
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Purpose/Objective: Stereotactic Body Radiation Therapy 
(SBRT) is emerging as a promising modality treatment in the 
management of genitourinary malignancies. The delivery of 
very high radiation doses in few fractions with a steep dose 
gradient may improve the therapeutic ratio in the treatment 
of prostate cancer. In this phase II study we tested the 
efficacy and the impact on toxicity of SBRT in patients with 
low or intermediate risk prostate cancer. 
Materials and Methods: Patients with low or intermediate 
risk prostate cancer histologically confirmed were enrolled in 
this phase II study. The treatment schedule was 35 Gy in 5 
fractions on alternate days, delivered with RapidArc in FFF 
modality. Toxicity was defined according to CT-CAE criteria 
v3.0 and classified as acute if occurring within 90 days from 
treatment and as late after 90 days. Patient-reported quality 
of life (QOL) relative to urinary, sexual and gastrointestinal 
symptoms was evaluated through EPIC questionnaires. 
Results: Between January 2012 and March 2014 73 patients 
were enrolled (46 low risk, 27 intermediate risk). At a median 
follow up of 18 months (range 3-30 months) all patients 
experienced a complete biochemical response. Acute toxicity 
was mild; only 8 % of patients presented a rectal G2-toxicity, 
while a maximum G2-GU toxicity was recorded in 43% of 
patients, mainly represented by urgency, dysuria and 
stranguria. Regarding late toxicity, a G1 proctitis was 
recorded in 6% of patients and a G1-GU (urgency, cystitis) in 
31%; only 1 event of G2 urinary toxicity was observed 
(transient urethral stenosis). No heavier adverse events 
occurred. EPIC questionnaires revealed a slight worsening in 
the urinary domains during treatment, with a return to 
baseline three months after treatment. No significant 
modifications in any of the other domains explored were 
reported. 
Conclusions: Stereotactic Body Radiotherapy appears to be 
an effective therapeutic option in low and intermediate risk 
prostate cancer patients, associated with a good compliance 
and tolerance of the treatment modality, and a low profile of 
late toxicity.  
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Purpose/Objective: To determine the relationship between 
acute genitourinary (GU) toxicity and dose distributions of GU 
pelvic structures in patients who received focal dose-
escalation IMRT for localized prostate cancer. To develop a 
methodology of assessing planned dose to the bladder trigone 
using dose surface maps (DSM).  
Materials and Methods: 50 patients with intermediate/high 
risk localized prostate cancer underwent radiotherapy (RT) 
within a prospective study (DELINEATE, ISRCTN04483921) 
which involved image-guided IMRT of 74Gy/37# to the 
prostate and 82Gy/37# to the dominant intra-prostatic 
nodule. The whole bladder and catheterized urethra were 
prospectively delineated. A bladder trigone surrogate 
structure was retrospectively contoured as a triangle-shaped 
region between the transition of the urethra into the bladder 
wall caudally and the transition of the ureters in the bladder 
cranially. Axially, the posterior of the contour described the 
extent of the bladder trigone. The contour was expanded 
anteriorly from the bladder wall (Fig. 1 red contour). A copy 
of this structure was created and the contour enlarged 
anteriorly and laterally only (Fig. 1 green contour). DSM were 
generated for both structures using dosimetric analysis 
software, VODCA (MSS GmBH, Hagendorn, CH). A subtraction 
method was developed using MATLAB (Mathworks, Natwick, 
MA) to establish the dosimetric region of coincidence 
between the two DSMs, defining the bladder trigone surface 
(Fig. 1c). Cumulative dose surface histograms (DSH) were 
generated for bladder trigone (BT). In addition, whole 
bladder (WB) DSH and DVH for urethra were created in 
VODCA. 
